Tuesday, May 11, 2021
Home Latest Pharma-News Zydus ‘Virafin’ receives Emergency Use Approval from DCGI moderate COVID-19 infection in...

Zydus ‘Virafin’ receives Emergency Use Approval from DCGI moderate COVID-19 infection in adults

April 23, 2021: Zydus Cadila announced that the company has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.

A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients.

- Advertisement -

When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications.

Virafin will be available on the prescription of medical specialist for use in
hospital/institutional setup.


In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19.

The drug has also shown efficacy against other viral infections.


Speaking on the development, Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited said “The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management.

It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19.”

In its Phase III clinical trials, the therapy had shown better clinical improvement in the patients suffering from COVID-19.

During the trials, a higher proportion of patients administered with
PegIFN arm were RT PCR negative by day 7.

The drug ensures faster viral clearance and has several add-on advantages compared to other anti-viral agents.

Type I interferons are body’s first line of defense against many viral infections and Pegylated Interferon alpha-2b has been used to treat these infections successfully.

Interferon alpha has also been implicated as crucial in the protection against SARS-CoV-2 in the recent publications in the leading journal Science.

Furthermore, aging reduces the body’s ability to produce Interferon Alpha in response to viral infections and may be associated with the higher mortality observed with
COVID-19 in elderly patients.

Virafin when given early on during infection can replace this deficiency and aid a faster recovery process.


Zydus acknowledges the support of BIRAC, in the development of Virafin for the treatment ofCOVID-19.”

https://zyduscadila.com/public/pdf/pressrelease/Press_Release_Zydus_receives_Emergency_Approval_for_the_use_of_Pegylated_Interferon_alpha_2b_23_4_2021.pdf

LEAVE A REPLY

Please enter your comment!
Please enter your name here

fifteen + fifteen =

Most Popular

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research

May 6, 2021: Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the...

Imfinzi, tremelimumab combo boosts survival in lung cancer

May 07, 2021: "POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in...

Vectura and Inspira Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

May 06, 2021: "Vectura Group plc, an industry leading inhalation CDMO, and Inspira Pharmaceuticals Limited, a new UK-based company focused on developing therapies...

Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants

April 26, 2021: The MELODY Phase III trial for nirsevimab met its primary endpoint of a statistically significant reduction in the incidence...